Cyprotex PLC (LSE:CRX) - Overview

Stock Report

Cyprotex PLC CRX

Last Price
GBX159.16

Day Change
-0.34|-0.21%

As of 09/12/2016
13:39:01 GMT | GBX
Minimum 15 Minutes Delay.

Last Close159.50p
Day Range159.16 - 159.25
Mkt Cap35.90Mil
52-Wk Range79.22 - 159.89
Yield %0.00
ISINGB00BP25RZ14
Volume3,156
P/E-5.49
P/S2.29
P/CF10.08

Share Price

Total Returns 08/12/2016

 Chg (%)  
More ...
Cyprotex PLC1.59 
FTSE 100 TR GBP1.73
 
Financials
201320142015
More ...
Income Statement
Turnover9.7711.5715.61
Operating Profit0.61-3.751.98
Net Profit-0.80-4.17-6.51
Reported EPS-35.60-18.59-28.99
Balance Sheet
Current Assets9.777.4210.12
Non Current Assets7.745.635.35
Total Assets17.5113.0415.47
Current Liabilities2.011.411.83
Total Liabilities11.1910.6019.24
Total Equity6.312.45-3.78
Cash Flow
Operating Cash Flow1.54-1.323.48
Net Change in Cash6.24-4.172.48
Broker Forecasts
Year EndingPre-taxEPSEPSgP/EPEGDPSYld %
More ...
'Broker Forecasts' provides consensus figures based on several brokers' views
--------
--------

Company Profile

Cyprotex PLC together with its subsidiaries provides in vitro and in silico ADMET and PK (absorption, distribution, metabolism, excretion, toxicity, and pharmacokinetics) information to the pharmaceutical and biotechnology industry.
 

Sector

Biotechnology

Market Position

1179 of 1863 Companies

Index

FTSE AIM All Share

Outlook

(02/08/2016) ch - "...the board looks forward to the remainder of the year with continued confidence"

Next Event 31/12/2016

Next year end (to be reported)
Ratios
CompSecMkt
More ...
PER (E)0.0013.3915.97
Div Yld (E)0.004.244.18
PEG (E)0.000.220.27
ROCE-156.79204.18-30.67
Op Mrgn-39.01-17.37-33.06
EPS Grwth0.009.7722.66
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00

Broker Sentiment

Strong Buy0
Buy0
Hold0
Sell0
Strong Sell0
  • Strong Sell
  • Strong Buy
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
More ...
Disclaimer
Directors
More ...
ChairmanMr Ian Johnson
Chief Executive OfficerDr Tony Baxter
Chief Financial OfficerJohn Dootson
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at Trafford House, Chester Road, Manchester M32 0RS. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2016 Morningstar. All rights reserved.